Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 3/20 | 0.60 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.60 |
| ▸ | HTT | P42858 | 1/20 | 0.60 |
| ▸ | AGTR1 | P30556 | 3/20 | 0.59 |
| ▸ | MEN1 | O00255 | 2/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.55 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | CA1 | P00915 | 3/20 | 0.35 |
| ▸ | CA2 | P00918 | 3/20 | 0.35 |
| ▸ | CA9 | Q16790 | 1/20 | 0.33 |
| ▸ | CES1 | P23141 | 2/20 | 0.33 |
| ▸ | BCHE | P06276 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11028130 | 0.84 | MAPT (0.60) | MAPTALDH1A1HTTAGTR1MEN1 | |
| SCHEMBL11028131 | 0.84 | MAPT (0.60) | MAPTALDH1A1HTTAGTR1MEN1 | |
| SCHEMBL5741222 | 0.78 | POLB (0.51) | MAPTALDH1A1HTTMEN1KMT2A | |
| SCHEMBL7827616 | 0.78 | MAPT (0.52) | MAPTALDH1A1HTTAGTR1MEN1 | |
| SCHEMBL11027185 | 0.76 | ALDH1A1 (0.58) | MAPTALDH1A1HTTAGTR1MEN1 | |
| SCHEMBL11027188 | 0.76 | ALDH1A1 (0.58) | MAPTALDH1A1HTTAGTR1MEN1 | |
| SCHEMBL5739112 | 0.75 | CES1 (0.50) | MAPTALDH1A1HTTAGTR1MEN1 | |
| SCHEMBL11025705 | 0.74 | MAPT (0.53) | MAPTALDH1A1HTTAGTR1MEN1 | |
| SCHEMBL11030290 | 0.70 | ALDH1A1 (0.46) | MAPTALDH1A1HTTAGTR1MEN1 | |
| SCHEMBL11030281 | 0.70 | ALDH1A1 (0.46) | MAPTALDH1A1HTTAGTR1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9199920-B2 | Antiviral drugs for treatment of arenavirus infection | Kineta Four, LLC (US) | 2015-12-01 | — | — | US | claimed |
| US-8492434-B2 | Antiviral drugs for treatment of arenavirus infection | SIGA TECHNOLOGIES INC. (US) | 2013-07-23 | — | — | US | claimed |
| US-20130165493-A1 | Antiviral Drugs for Treatment of Arenavirus Infection | Siga Technologies, Inc, (US) | 2013-06-27 | — | — | US | claimed |
| US-8492434-B2 | Antiviral drugs for treatment of arenavirus infection | SIGA TECHNOLOGIES INC. (US) | 2013-07-23 | — | — | US | disclosed |
| US-20130165493-A1 | Antiviral Drugs for Treatment of Arenavirus Infection | Siga Technologies, Inc, (US) | 2013-06-27 | — | — | US | disclosed |
| US-20090036513-A1 | Antiviral Drugs for Treatment of Arenavirus Infection | SIGA TECHNOLOGIES, INC. (US) | 2009-02-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130165493-A1 | Antiviral Drugs for Treatment of Arenavirus Infection | GK, ZC3HAV1, GALK1 | MAPT 814/4885ALDH1A1 4066/4885HTT 2597/4885 |
| US-20090036513-A1 | Antiviral Drugs for Treatment of Arenavirus Infection | GK, ZC3HAV1, GALK1 | MAPT 814/4885ALDH1A1 4066/4885HTT 2597/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.